The two-way relationship between medical illness and late-life depression.

This article reviews some common medical conditions and the interaction between those illnesses and depression in the geriatric population. The authors aim to help clarify the 2-way interaction between depression and these medical conditions, especially in older individuals, and impart some important diagnostic and treatment considerations to the practicing physician. The presence of multiple conditions further complicates treatment, as does associated medication use, substance abuse problems (often underappreciated in the elderly), age-related changes in sleep architecture, and an array of other psychosocial and environmental factors that can contribute to the development of depression.

Psychiatric care of the patient with hepatitis C: a review of the literature.

Context: Approximately 1.8% of the US population is chronically infected with the hepatitis C virus (HCV). The prevalence rates of psychiatric illness in patients with HCV infection are higher than those rates in the general US population, and the prevalence of HCV infection in patients with severe mental illness may be as high as 9 times that of the general US population.

Preventing relapse of major depression during interferon-alpha therapy for hepatitis C--A pilot study.

Depression is common in hepatitis C, exacerbated by interferon, and is a major reason for discontinuing interferon therapy. We aimed to determine (1) whether patients with a history of major depression could complete a course of peginterferon alpha-2a and ribavirin if pretreated with escitalopram and (2) the relapse rate of depression during the course of therapy in these subjects. Ten patients were enrolled in the study and treated with escitalopram.

Major depressive disorder in hepatitis C: an open-label trial of escitalopram.

Background: Depression is a common condition associated with hepatitis C and may be induced by interferon alfa, the primary treatment for hepatitis C. Depression is also a major barrier to the initiation of such treatment. This study examined the effect of escitalopram on measures of depression, quality of life, and tests of liver function in subjects with comorbid hepatitis C and depression.

Plasma levels of citalopram in depressed patients with hepatitis C.

Hepatitis C affects an estimated 4 million Americans and 100 million people worldwide. Rates of depression are higher than that seen in the general population. Antidepressant therapy is often initiated at lower doses in patients with liver disease because of concerns about impaired metabolism and clearance.

Delirium.

Delirium is characterized by an acute change in cognition and a disturbance of consciousness, usually resulting from an underlying medical condition or from medication or drug withdrawal. Delirium affects 10 to 30 percent of hospitalized patients with medical illness; more than 50 percent of persons in certain high-risk populations are affected. The associated morbidity and mortality make diagnosis of this condition extremely important.

An open-label trial of citalopram for major depression in patients with hepatitis C.

Background: Hepatitis C affects nearly 4 million Americans. Depression is a common comorbid condition in this population and may be induced by interferon alfa, an approved treatment for hepatitis C. Depression is a major indicator for discontinuation of interferon therapy.